BioSpace News Archive

Axcella Therapeutics (Nasdaq: AXLA) today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.

XORTX Therapeutics Inc. announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences.

AI Proteins, the biotechnology company using artificial intelligence to design synthetic proteins de novo, announced its public launch and the close of an oversubscribed $18.2 million seed series co-led by Cobro Ventures and Lightchain Capital.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present data in a poster at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Incyte will present data from its oncology portfolio at the upcoming 64th American Society of Hematology Annual Meeting, held December 10-13, 2022, in New Orleans and virtually.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim NEO2™ IPG.

Intelivation Technologies, a medical device company with a cutting-edge orthopedic portfolio announced today that they are launching the InletTM System of comprehensive plating and fixation options for upper and lower extremity applications.

AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System.

Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 – 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF).

MaaT Pharma (EURONEXT: MAAT – the “Company”) announced today that extended results from its Early Access Program (EAP) of MaaT013 in patients with GI-aGvHD have been selected for oral presentation at the 64thAmerican Society of Hematology (ASH) Annual Meeting held from December 10-13, 2022, in New-Orleans, Louisiana, U.S.A.